Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Watson Pharmaceuticals
This study will use a multicenter, randomized, open-label, active-controlled, dose-titration, parallel group design, in approximately pediatric patients with detrusor overactivity associated with a neurological condition.
Age
6–15
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Pediatric patient with a diagnosis of detrusor overactivity associated with a neurological condition;
Use clean intermittent catheterization
On stable dose of oral oxybutynin before participation
You may not be if
Have one or more treatable conditions, other than neurogenic bladder dysfunction, that may cause urinary incontinence or urgency
Have any medical condition that precludes their participation in the study or may confound the outcome of the study
Clareo Health | Safety and Efficacy Study of Transdermal Oxybutynin to Treat Overactive Bladder With a Neurological Condition
